Oncolytics Biotech IncONCY

Oncolytics Biotech Inc. has $5.5 million in cash and $13.3 million in liabilities, leaving shareholders nursing a $5.1 million deficit on the balance sheet for the quarter ended 31 March 2026. Operating losses stood at $9.3 million and net losses at $9.2 million, while diluted loss per share clocked in at $0.08 on 112.3 million shares. The company burned $7.3 million of cash from operations, a pace that would exhaust the current cash pile in roughly 19 payroll cycles if executives agreed to be paid in exposure and good press releases.

Pelareorep, the firm’s lead intravenous double-stranded RNA immunotherapeutic, remains in clinical testing; Oncolytics reported on 13 July 2026 that half of planned clinical sites for its randomised RAS-mutant MSS colorectal cancer trial are expected to activate this month. The company also disclosed that more than 20 patients have been pre-identified across participating centres, a step forward that sounds substantive until you remember the balance sheet has no revenues to offset the pivot.

The 10-Q shows research and development expense of $4.6 million for the quarter, while capital expenditure was a rounding error at $6,000-illustrating a business that is spending on trials but not yet on bricks. Total assets of $8.2 million sit against total liabilities of $13.3 million, giving shareholders negative equity of $5.1 million. Cash and equivalents finished the quarter at $5.5 million, a figure that covers roughly one more quarter of operations at current burn.

The company’s investor rail has been busy with regulatory theatrics. On 20 July 2026, Oncolytics disclosed that the FDA granted Fast Track designation to pelareorep for second-line and later anal cancer, a label designed to accelerate development in a roughly $1 billion market where no FDA-approved therapies exist. On 16 June 2026, the firm announced a new U.S. patent protecting the commercial manufacturing process for pelareorep through 2044, a filing that protects processes it has not yet used at commercial scale. The same release confirms pelareorep is an intravenously delivered double-stranded RNA immunotherapeutic agent under investigation-an elegant description, but one that does not yet translate into revenue.

The SEC filings do not include revenue, gross margin, or earnings guidance; the company’s most recent 10-Q is the latest available public disclosure and carries no segment-level revenue breakdown or cash flow statement beyond the headline numbers already cited. The filing index on SEC EDGAR lists the 10-Q, 8-Ks, and ownership XML as the primary disclosures; no 10-K or audited annual report is cited in the evidence and no dividend, buyback, or equity raise is disclosed in the supplied documents.

For investors wondering where the stock trades, the evidence rail provides The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The filing evidence is thin on operating metrics and heavy on developmental milestones, leaving the core tension between clinical promise and cash scarcity unresolved.

The next meaningful source-backed update would be the next 10-Q or 8-K that discloses cash burn, cash runway, or concrete revenue events; until then, the story remains a clinical-stage biotech with promising pipeline chatter and a balance sheet that prefers to stay in the red.